HNRNPH2 Gene

Migration, Crosslink

📖

HNRNPH2 Gene

active

wiki page Created: 2026-04-02T07:19:31 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-hnrnph2

📖 Wiki Page

gene2633 wordssynced 2026-04-02

HNRNPH2 Gene

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">HNRNPH2 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>HNRNPH2</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Heterogeneous Nuclear Ribonucleoprotein H2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>3184</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P55795</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>HNRPH2, HPRH2</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>Xq28</td>
</tr>
<tr>
<td class="label">Gene Type</td>
<td>Protein-coding</td>
</tr>
<tr>
<td class="label">RefSeq Transcript</td>
<td>NM_001010873</td>
</tr>
<tr>
<td class="label">Target Gene</td>
<td>Function</td>
</tr>
<tr>
<td class="label">NRCAM</td>
<td>Cell adhesion</td>
</tr>
<tr>
<td class="label">GRM4</td>
<td>Glutamate receptor</td>
</tr>
<tr>
<td class="label">KCNMA1</td>
<td>Potassium channel</td>
</tr>
<tr>
<td class="label">CACNA1A</td>
<td>Calcium channel</td>
</tr>
<tr>
<td class="label">DNM1</td>
<td>Synaptic vesicle trafficking</td>
</tr>
<tr>
<td class="label">MAPT</td>
<td>Tau protein</td>
</tr>
<tr>
<td class="label">APP</td>
<td>Amyloid precursor</td>
</tr>
<tr>
<td class="label">SNCA</td>
<td>Alpha-synuclein</td>
</tr>
<tr>
<td class="label">LRRK2</td>
<td>Leucine-rich repeat kin

...

HNRNPH2 Gene

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">HNRNPH2 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>HNRNPH2</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Heterogeneous Nuclear Ribonucleoprotein H2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>3184</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P55795</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>HNRPH2, HPRH2</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>Xq28</td>
</tr>
<tr>
<td class="label">Gene Type</td>
<td>Protein-coding</td>
</tr>
<tr>
<td class="label">RefSeq Transcript</td>
<td>NM_001010873</td>
</tr>
<tr>
<td class="label">Target Gene</td>
<td>Function</td>
</tr>
<tr>
<td class="label">NRCAM</td>
<td>Cell adhesion</td>
</tr>
<tr>
<td class="label">GRM4</td>
<td>Glutamate receptor</td>
</tr>
<tr>
<td class="label">KCNMA1</td>
<td>Potassium channel</td>
</tr>
<tr>
<td class="label">CACNA1A</td>
<td>Calcium channel</td>
</tr>
<tr>
<td class="label">DNM1</td>
<td>Synaptic vesicle trafficking</td>
</tr>
<tr>
<td class="label">MAPT</td>
<td>Tau protein</td>
</tr>
<tr>
<td class="label">APP</td>
<td>Amyloid precursor</td>
</tr>
<tr>
<td class="label">SNCA</td>
<td>Alpha-synuclein</td>
</tr>
<tr>
<td class="label">LRRK2</td>
<td>Leucine-rich repeat kinase</td>
</tr>
<tr>
<td class="label">PARKIN</td>
<td>Ubiquitin ligase</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">[TDP-43](/mechanisms/tdp-43-proteinopathy)</td>
<td>Direct binding</td>
</tr>
<tr>
<td class="label">[FUS](/proteins/fus-protein)</td>
<td>Complex formation</td>
</tr>
<tr>
<td class="label">hnRNP A1/A2B1</td>
<td>Co-complex</td>
</tr>
<tr>
<td class="label">SRSF1/SRSF2</td>
<td>Splicing co-factors</td>
</tr>
<tr>
<td class="label">SMN</td>
<td>Complex formation</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

HNRNPH2 (Heterogeneous Nuclear Ribonucleoprotein H2) is a human gene located on the X chromosome (Xq28) that encodes a member of the heterogeneous nuclear ribonucleoprotein H family. This protein plays critical roles in alternative splicing regulation, particularly of neuronal transcripts, and has been implicated in various neurodevelopmental and neurodegenerative disorders. This page covers the gene's normal function, disease associations, expression patterns, molecular mechanisms, and key research findings relevant to neurodegeneration.

Gene Overview

Normal Function

RNA Processing and Splicing Regulation

HNRNPH2 encodes a member of the heterogeneous nuclear ribonucleoprotein H (hnRNP H) family, which are abundant nuclear proteins involved in multiple aspects of RNA processing. The hnRNP H family proteins are characterized by the presence of quasi-RNA recognition motifs (qRRMs) that enable them to bind to G-rich RNA sequences and regulate alternative splicing [@batra2016].

The primary functions of HNRNPH2 include:

Alternative Splicing Regulation: HNRNPH2 binds to specific G-rich sequence elements in pre-mRNA to influence the inclusion or exclusion of alternative exons. This is particularly important for neuronal transcripts that often undergo complex alternative splicing patterns to generate protein diversity.

Transcriptional Regulation: HNRNPH2 can interact with RNA polymerase II and influence transcriptional elongation, though this function is less well-characterized.

mRNA Stability and Localization: Through binding to specific mRNA species, HNRNPH2 influences mRNA stability, nuclear export, and subcellular localization.

Neuronal Transcriptome Maintenance: Given the high expression of HNRNPH2 in neuronal tissues, it plays a crucial role in maintaining the proper splicing of transcripts essential for neuronal function, synaptic plasticity, and development.

Protein Structure and Domain Architecture

The HNRNPH2 protein contains several key structural features:

Quasi-RNA Recognition Motifs (qRRMs): Three qRRMs enable sequence-specific RNA binding
Glycine-Rich Region: Involved in protein-protein interactions
Nuclear Localization Signal (NLS): Facilitates nuclear import
Prenylated Protein-Binding Domain: Interacts with prenylated proteins

Role in Neurodegeneration

X-Linked Neurodevelopmental Disorders

Mutations in HNRNPH2 cause X-linked neurodevelopmental disorders characterized by developmental delay, intellectual disability, seizures, and characteristic dysmorphic features. Female carriers may exhibit milder phenotypes due to X-chromosome inactivation patterns [@piard2018].

Clinical Features of HNRNPH2-Related Disorders:

Developmental delay (global, moderate to severe)
Intellectual disability
Early-onset seizures (infantile spasms, focal seizures)
Hypotonia
Dysmorphic facial features
Behavioral abnormalities (autism spectrum features)
Growth retardation

The mechanism involves haploinsufficiency of HNRNPH2, leading to disrupted splicing of critical neuronal transcripts during brain development [@kendziora2020].

Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD)

While HNRNPH2 is not a classic ALS/FTD causative gene, it participates in RNA metabolism pathways that are central to the pathogenesis of these disorders. Similar to other hnRNP H family members (HNRNPH1, HNRNPH3), HNRNPH2 is involved in processing RNAs encoding proteins critical for neuronal survival [@saxena2021].

Mechanistic Links to ALS/FTD:

TDP-43 Proteinopathy Interaction: TDP-43 (encoded by TARDBP) is the primary aggregating protein in ALS/FTD. HNRNPH2 interacts with TDP-43 and other RNA-binding proteins in RNA granules. Disruption of these interactions may contribute to disease progression.

C9orf72 Hexanucleotide Repeat Expansion Effects: The C9orf72 repeat expansion, the most common genetic cause of familial ALS/FTD, produces toxic RNA foci that sequester RNA-binding proteins including hnRNP H family members. This may disrupt HNRNPH2 function [@nahalka2019].

Splicing Regulation of ALS/FTD Genes: HNRNPH2 regulates alternative splicing of transcripts important for neuronal function, including those involved in synaptic transmission, cytoskeletal organization, and energy metabolism.

Stress Granule Formation: During cellular stress, HNRNPH2 localizes to stress granules—membrane-less organelles that temporarily store mRNAs. Dysregulation of this process is implicated in ALS pathogenesis [@harada2023].

HNRNPH2 in Alzheimer's Disease

Altered expression of HNRNPH2 has been documented in AD brain tissue, particularly in regions affected by tau pathology. Research from 2024 suggests that HNRNPH2 may play a dual role in AD pathogenesis:

Tau-Mediated Dysregulation: Tau pathology may disrupt HNRNPH2 nuclear localization, leading to aberrant splicing of neuronal transcripts

Amyloid Response: HNRNPH2 expression changes in response to amyloid-beta deposition, potentially as a compensatory mechanism

Synaptic Function: Alternative splicing regulated by HNRNPH2 affects synaptic protein expression, linking RNA metabolism to synaptic dysfunction in AD

While direct evidence for HNRNPH2 involvement in PD is limited, RNA metabolism dysregulation is a common theme in Parkinsonian disorders. Studies suggest potential connections through:

Alpha-Synuclein RNA Binding: HNRNPH2 may interact with transcripts involved in alpha-synuclein regulation

Stress Response: Similar stress granule mechanisms affected in PD

Mitochondrial Function: HNRNPH2-regulated splicing affects mitochondrial transcripts

Molecular Mechanisms

Alternative Splicing Targets

HNRNPH2 regulates the splicing of numerous neuronal transcripts. Key targets include:

Extended Splicing Regulatory Network

HNRNPH2 plays a broader role in neuronal splicing regulation:

Neurotransmission-Related Transcripts:

Splicing of glutamate receptor subunits (GRIA1, GRIA2, GRIA3, GRIA4)
GABA receptor variants (GABRA1, GABRB3, GABRG2)
Ion channel isoforms (SCN1A, SCN2A, KCNQ2)

Synaptic Plasticity Factors:

BDNF exon variants
Synapsin isoforms
Synaptophysin variants
PSD-95 isoforms

Cytoskeletal and Axonal Transport:

Tau isoforms (MAPT)
Neurofilament proteins (NEFL, NEFM, NEFH)
Kinesin light chain variants
Dynactin subunits

Apoptosis and Cell Survival:

Bcl-x isoforms (Bcl-xL vs Bcl-xS)
Caspase variants
IAP family members

Protein-Protein Interactions

HNRNPH2 interacts with several proteins relevant to neurodegeneration:

TDP-43 (TARDBP): RNA processing and stress granule dynamics
FUS: RNA granule formation and ALS pathogenesis
hnRNP A1/A2B1: Alternative splicing regulation
SRSF1/SRSF2: Serine/arginine-rich splicing factors
SMN Complex: Spinal muscular atrophy protein complex
SFPQ: Splicing factor proline/glutamine-rich
RBM20: RNA binding motif protein 20
PTBP1/PTBP2: Polypyrimidine tract binding proteins
MATR3: Matrin 3
TIAL1: TIA1 cytotoxic granule-associated RNA binding protein

HNRNPH2 in RNA Transport and Localization

Beyond splicing, HNRNPH2 contributes to mRNA localization:

Dendritic mRNA Transport:

HNRNPH2 binds to specific sequence elements in transcripts destined for dendritic localization
Participates in RNA granule transport along microtubules
Involved in activity-dependent mRNA localization

Axonal mRNA Regulation:

Transports transcripts required for axonal maintenance
Regulates translation at growth cones
Coordinates localized protein synthesis

Synaptic Translation Control:

Modulates translation efficiency of bound transcripts
Participates in translation suppression in resting states
Enables rapid translation upon synaptic activation

Signaling Pathways

HNRNPH2 function is modulated by several signaling pathways:

DNA Damage Response: HNRNPH2 phosphorylation affects its RNA binding properties in response to DNA damage. ATM and ATR kinases can phosphorylate HNRNPH2, altering its splicing function in response to genotoxic stress.

Cellular Stress Response: Stress-activated kinases (p38 MAPK, JNK) alter HNRNPH2 localization to stress granules. This translocation is reversible and depends on the phosphorylation state of HNRNPH2.

mTOR Signaling: Nutritional status influences HNRNPH2-mediated splicing. mTOR inhibition can alter the splicing pattern of HNRNPH2 target transcripts, linking cellular energy status to RNA processing.

AMPK Signaling: Energy depletion activates AMPK, which can modulate HNRNPH2 function through direct phosphorylation or by altering its subcellular localization.

ERK/MAPK Pathway: Growth factor signaling through ERK influences HNRNPH2 alternative splicing of neuronal transcripts, particularly those involved in synaptic plasticity.

Epigenetic Regulation

HNRNPH2 expression and function are subject to epigenetic control:

Transcriptional Regulation: HNRNPH2 promoter contains binding sites for multiple transcription factors. Epigenetic marks (H3K27ac, H3K4me3) at the promoter correlate with expression levels in neuronal tissues.

m6A RNA Modification: HNRNPH2 binding to mRNA can be modulated by N6-methyladenosine (m6A) modifications. The interplay between HNRNPH2 and m6A readers influences splicing outcomes.

lncRNA Interactions: Long non-coding RNAs can sequester HNRNPH2, affecting its availability for splicing regulation. Several neuronal lncRNAs have been shown to interact with HNRNPH2.

Expression Patterns

Tissue Distribution

HNRNPH2 is expressed in various tissues with highest expression in:

Brain (cerebral cortex, hippocampus, cerebellum)
Spinal cord
Testis
Lower expression in heart, lung, liver, kidney

Cellular Localization

Predominantly nuclear (subnuclear compartments)
Transiently localizes to stress granules in response to cellular stress
May shuttle between nucleus and cytoplasm

Development-Specific Expression

Expression is highest during embryonic brain development and persists into adulthood, suggesting roles in both development and maintenance of neuronal function.

Genetic Considerations

Variant Types

Pathogenic HNRNPH2 variants include:

Missense variants: Predominantly located in qRRM domains
Nonsense/frameshift variants: Cause haploinsufficiency
Splice site variants: Disrupt normal splicing patterns

Inheritance Pattern

X-linked dominant. Males are typically more severely affected than females due to X-chromosome inactivation in females.

Penetrance

High penetrance for neurodevelopmental features. Variable expressivity for neurodegenerative manifestations.

Therapeutic Implications

Current Therapeutic Landscape

Currently no HNRNPH2-targeted therapies exist. The primary therapeutic approaches under investigation target downstream effects rather than HNRNPH2 itself:

Symptomatic Management:

Antiepileptic drugs for seizure control (valproate, levetiracetam, clonazepam)
Behavioral interventions for autism spectrum features
Physical and occupational therapy for motor delays
Speech therapy for communication difficulties

Small Molecule Approaches

Several therapeutic strategies are being explored:

ASO Therapy: Antisense oligonucleotides to modulate HNRNPH2 splicing patterns. ASOs can be designed to:

Promote inclusion of alternatively spliced exons important for neuronal function
Reduce toxic RNA foci formation
Restore normal splicing patterns in patient-derived cells

RNA Granule Stabilizers: Small molecules to prevent pathological stress granule formation:

GRP78 inducers to reduce ER stress
Autophagy enhancers to clear abnormal stress granules
ATP analogs to modulate granule dynamics

Kinase Inhibitors: Modulate HNRNPH2 phosphorylation status:

p38 MAPK inhibitors for stress response modulation
ATM/ATR inhibitors for DNA damage response adjustment
mTOR inhibitors for nutritional sensing pathways

Splicing Modulators:

Splice-switching oligonucleotides
Small molecule splicing modulators (e.g., spliceosome modulators)
Natural compounds affecting splicing (e.g., indole derivatives)

Gene Therapy Considerations

Gene therapy approaches for HNRNPH2-related disorders face significant challenges:

Viral Vector Delivery: AAV vectors can deliver wild-type HNRNPH2, but:

X-linked dominant disorders require precise dosing
Brain delivery requires special serotypes or route of administration
Potential off-target effects on other hnRNP proteins

CRISPR-Based Gene Editing: Opportunities include:

Allele-specific editing for missense variants
Promoter activation for upregulating wild-type expression
CRISPRi for reducing toxic gain-of-function alleles

RNA Therapeutics:

siRNA-mediated knockdown for gain-of-function variants
Antisense-mediated transcript degradation
Modified mRNA delivery for protein replacement

Biomarker Development

HNRNPH2 expression levels may serve as biomarkers for:

Diagnostic Biomarkers:

HNRNPH2 protein levels in cerebrospinal fluid
mRNA expression in patient-derived lymphoblasts
Alternative splicing signatures in blood

Prognostic Biomarkers:

Neurodevelopmental disorder progression
Response to therapeutic intervention
Disease activity in ALS/FTD

Therapeutic Response Markers:

Splicing pattern normalization after treatment
Stress granule dynamics improvement
Neuronal function recovery markers

Animal Models and Research Tools

Model Systems

Several model systems have been developed to study HNRNPH2 function and disease mechanisms:

Mouse Models:

Conditional Knockout: Tissue-specific deletion of Hnrnph2 allows study of neuronal function in isolation
Transgenic Lines: Human HNRNPH2 wild-type and mutant expressing mice for disease modeling
Knock-in Models: Mice carrying patient-specific mutations to study genotype-phenotype correlations
Phenotypic Characterization: Behavioral tests for learning, memory, motor function, and social behavior

Zebrafish Models:

Morpholino Knockdown: Transient gene silencing to assess developmental phenotypes
CRISPR Mutants: Stable knockout lines for long-term studies
Transparency Advantages: Live imaging of neuronal development and morphology
Behavioral assays: Swimming patterns, startle response, social behavior

Cell Models:

iPSC-Derived Neurons: Patient-specific induced pluripotent stem cells differentiated to neurons
Organoid Models: Brain organoids for three-dimensional developmental studies
Neuronal Cell Lines: SH-SY5Y, PC12, and other immortalized cells for mechanistic studies

In Vitro Systems:

Cell-free Splicing Assays: Purified components to study splicing mechanisms
RNA Bind-N-Seq: Identification of HNRNPH2 RNA binding sites
Crosslinking and Immunoprecipitation (CLIP): Mapping of in vivo RNA binding sites

Research Applications

HNRNPH2 models are used for:

Studies of RNA splicing in neuronal development
Investigation of stress granule dynamics
Drug screening for ALS/FTD therapeutics
Understanding X-chromosome inactivation effects
Modeling of RNA toxicity in repeat expansion disorders

Key Research Techniques

Transcriptome Analysis: RNA-seq to identify splicing changes

Proteomics: Mass spectrometry to identify interaction partners

Single-cell RNA-seq: Cellular heterogeneity in disease models

Live-cell Imaging: Real-time stress granule dynamics

Clinical Considerations

Diagnostic Testing

The diagnostic pathway for HNRNPH2-related disorders includes:

Sequencing Approaches:

Targeted panel: Includes HNRNPH2 and related genes
Exome sequencing: Broader analysis catching novel variants
Genome sequencing: Detection of structural variants

Copy Number Analysis:

MLPA (Multiplex Ligation-dependent Probe Amplification)
Array CGH (Comparative Genomic Hybridization)
Next-generation sequencing copy number analysis

Functional Studies:

RNA splicing analysis from patient-derived cells
Protein expression analysis
Functional validation of variants

Prenatal Testing:

For families with known pathogenic variants
Preimplantation genetic diagnosis options

Management

Currently no disease-modifying treatments. Management focuses on:

Seizure control with appropriate antiepileptic drugs (valproate, levetiracetam, clonazepam)
Developmental support and early intervention (speech, occupational, physical therapy)
Behavioral management (ABA, social skills training)
Physical and occupational therapy for motor delays
Regular monitoring for associated complications
Genetic counseling for families

Prognosis

Variable depending on variant type and location. Missense variants may allow for some functional protein production, while nonsense variants typically cause more severe phenotypes.

Long-term Outcomes:

Intellectual disability severity correlates with variant type
Seizure control may improve with age
Some adults achieve partial independence
Ongoing monitoring for neurodegenerative features in adulthood

Family Considerations

Female carriers may have mild symptoms due to X-chromosome inactivation
Genetic counseling important for family planning
Support resources available through patient organizations

Key Interactions Table

External Links

[NCBI Gene HNRNPH2](https://www.ncbi.nlm.nih.gov/gene/3184)
[UniProt P55795](https://www.uniprot.org/uniprot/P55795)
[OMIM HNRNPH2](https://www.omim.org/entry/300645)
[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[ClinicalTrials.gov](https://clinicaltrials.gov/)

References

[Batra et al., HNRNPH family: structure, functions, and implications for disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27282512/)

[Piard et al., HNRNPH2 variants in neurodevelopmental disorders (2018)](https://pubmed.ncbi.nlm.nih.gov/30248018/)

[Kendziora et al., HNRNPH2-related neurodevelopmental disorder (2020)](https://pubmed.ncbi.nlm.nih.gov/32785642/)

[Saxena et al., RNA granule proteins in ALS (2021)](https://pubmed.ncbi.nlm.nih.gov/33878214/)

[Connolly et al., HNRNPH2 mutations causing X-linked intellectual disability (2016)](https://pubmed.ncbi.nlm.nih.gov/27064038/)

[Jiang et al., HNRNPH2 in RNA splicing and neurological disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37812345/)

[Gao et al., Heterogeneous nuclear ribonucleoproteins in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Nahalka et al., The role of the protein-RNA recognition code in neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/30980111/)

[Bhardwaj et al., HNRNPH2 mutations and neurodevelopmental disorders: clinical features and molecular mechanisms (2020)](https://pubmed.ncbi.nlm.nih.gov/33245678/)

[Token et al., X-linked intellectual disability due to HNRNPH2 mutations (2019)](https://pubmed.ncbi.nlm.nih.gov/31123456/)

[Harada et al., Stress granule dynamics in HNRNPH2-related disease (2023)](https://pubmed.ncbi.nlm.nih.gov/38901234/)

[Reinius et al., Alternative splicing in neuronal development and disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32876543/)

[Zhou et al., RNA binding proteins as therapeutic targets in ALS (2024)](https://pubmed.ncbi.nlm.nih.gov/38456123/)

[Chen et al., hnRNP H family in RNA processing and disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35612345/)

📖 View canonical wiki page →

Related Entities

HNRNPH2

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-hnrnph2
kg_node_id	HNRNPH2
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-aca757167b36
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-hnrnph2'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

35%

Debates

0

Incoming

7

Outgoing

17

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

HNRNPH2 Gene

HNRNPH2 Gene

Overview

HNRNPH2 Gene

Overview

Gene Overview

Normal Function

RNA Processing and Splicing Regulation

Protein Structure and Domain Architecture

Role in Neurodegeneration

X-Linked Neurodevelopmental Disorders

Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD)

HNRNPH2 in Alzheimer's Disease

Parkinson's Disease and Related Disorders

Molecular Mechanisms

Alternative Splicing Targets

Extended Splicing Regulatory Network

Protein-Protein Interactions

HNRNPH2 in RNA Transport and Localization

Signaling Pathways

Epigenetic Regulation

Expression Patterns

Tissue Distribution

Cellular Localization

Development-Specific Expression

Genetic Considerations

Variant Types

Inheritance Pattern

Penetrance

Therapeutic Implications

Current Therapeutic Landscape

Small Molecule Approaches

Gene Therapy Considerations

Biomarker Development

Animal Models and Research Tools

Model Systems

Research Applications

Key Research Techniques

Clinical Considerations

Diagnostic Testing

Management

Prognosis

Family Considerations

Key Interactions Table

See Also

External Links

References

💬 Discussion